Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  35.00 5.74% 645.00 620.00 650.00 635.00 610.00 610.00 241,250 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 383

Renalytix Ai Share Discussion Threads

Showing 301 to 324 of 600 messages
Chat Pages: 24  23  22  21  20  19  18  17  16  15  14  13  Older
DateSubjectAuthorDiscuss
09/7/2020
12:37
Hi Pug.Main events are KidneyIntelX and the forthcoming NDQ listing.The spinoff business is rather a side show for me. Will most likely sell any shares to buy more RENX when the time comes.
longshanks
09/7/2020
11:53
May have missed it, but what are peoples thoughts on the distrbution of shares in Verci and the lock-in periods -
pugugly
08/7/2020
11:43
Yes, which I confirm is exactly what happened when EKF Diagnostics spun-off Renalytix, with the resulting Renalytix shares showing in my ISA alongside my EKF holding.
wan
08/7/2020
11:14
are you entitled within an isa?
harleymaxwell
08/7/2020
09:33
Yes, that’s what it says...
74tom
08/7/2020
09:26
If I buy today will I be on the register on the 9th?? CD
cambridgedon
08/7/2020
08:50
thanks - website and company info really isn't very well presented or sizeable, which is a bit at odds with the quality of information that has been flowing.
2theduke
08/7/2020
08:47
All ducks aligning well.I see a compelling value proposition for using KidneyIntelX with all CKD patients as it helps prioritise which patients actually need the most expensive treatments available.Insurers will love it.
longshanks
08/7/2020
08:25
The Partnership Agreement is indeed excellent news, and further demonstrating managements track record to date of consistently executing on their strategy. Worth a look - America’s Choice Provider Network hTTp://www.acpnusa.com/
wan
08/7/2020
08:06
Ok thanks guys - helpful. I’ll look to confirm the ISA Point in due course but that’s helpful. Re the disclosure , helpful again as I was reading it as they maybe disposing shares. Great and prompt feedback - no doubt we’re all doing well here, this company has real momentum.
2theduke
08/7/2020
08:04
I added again yesterday and I’m pretty happy about that. Today’s partnership news is superb.
mr roper
08/7/2020
08:01
The Duke...If your Renalytix shares are in your ISA, then it follows that your Verici DX shares, which are effectively a dividend, will automatically be in the ISA too. From what I can tell, the related party element covers Mount Sinai if there were any lawsuits issued with regard to any apparent misinformation in connection to the listing of the shares in the US. After all, Mount Sinai are a hospital not a trading entity, nor indeed experts in the buying and selling of shares, so it seem reasonable to me, if I have understood it correctly.
wan
08/7/2020
07:59
You’ve missed the second part of that disclosure, I read it as a standard part of the dual listing process - key thing being it’s only relevant in the case of a material misstatement... Related party transaction “As part of RenalytixAI's preparations for a potential dual-listing on Nasdaq, The Icahn School of Medicine at Mount Sinai ("Mount Sinai"), a substantial shareholder in the Company, has requested that RenalytixAI enter into a registration rights agreement pursuant to which RenalytixAI will, at its own cost and expense, assist Mount Sinai in the registration of Mount Sinai's ordinary shares for resale under the U.S. Securities Act of 1933, as amended. The registration rights agreement contains customary indemnities given by RenalytixAI in respect of any loss suffered by Mount Sinai and certain of its associated persons (as well as the underwriters on any underwritten follow-on offering by Mount Sinai) arising out of any material misstatements made in or omissions from the public filings related to the potential Nasdaq dual-listing and/or the resale of Mount Sinai's ordinary shares. These indemnities are of a customary nature and are uncapped.“
74tom
08/7/2020
07:58
This will easily double post nasdaq listing
nimbo1
08/7/2020
07:58
If your renx shares are in ISA these will end up there
charlieej
08/7/2020
07:49
this sounds very good: " Under the agreement, RenalytixAI will now be able to offer KidneyIntelX testing to diabetic kidney disease patients among ACPN's more than 30 million members in the US. "
netcurtains
08/7/2020
07:48
Another questions - the questions in trust. Any idea how these can be placed in an ISA like my renx shares are? I’m a bit concerned about potential tax liabilities - has anyone been through this before?
2theduke
08/7/2020
07:44
Morning all, a bit to digest here and reads well. Could someone explain in a bit more detail what the following means? “ Related party transaction As part of RenalytixAI’s preparations for a potential dual-listing on Nasdaq, The Icahn School of Medicine at Mount Sinai (“Mount Sinai”), a substantial shareholder in the Company, has requested that RenalytixAI enter into a registration rights agreement pursuant to which RenalytixAI will, at its own cost and expense, assist Mount Sinai in the registration of Mount Sinai’s ordinary shares for resale under the U.S. Securities Act of 1933, as amended. ”
2theduke
08/7/2020
07:28
It’s all going on... Firstly, nice to see more progress on the VericiDX front, makes sense from an administration point of view, the value of the new shares will be determined when they IPO but it’s split off pre Nasdaq listing. The network coverage RNS is the big news though, highlights are; “Under the agreement, RenalytixAI will now be able to offer KidneyIntelX testing to diabetic kidney disease patients among ACPN's more than 30 million members in the US.“ Todd Breeden, CEO of ACPN , said: "ACPN is very excited to announce our new relationship with RenalytixAI. We are pleased to offer their first of its kind KidneyIntelX test to help guide chronic kidney disease care delivery. CKD is a significant challenge faced by our network of providers, payers and members. This test is uniquely positioned to potentially improve care and outcomes and reduce healthcare spending. Our partnership with RenalytixAI shows ACPN's commitment to add progressive, cutting edge companies to our national provider network." Truly impressive progress on all fronts at present, momentum is building :)
74tom
07/7/2020
15:48
The exciting thing about RENX is the combination of huge addressable target market, the presence of a significant and growing IP moat & the macro tailwinds driving market appetite for health-tech companies (especially those listed in the US). For these reasons alone the escalator can go an awful lot higher over the coming years. Stifel have forecast revenues of $390m in 5 years time. Comparators such as Guardant Health reported $67m revenue last quarter & are valued at over $8b. So evidently IF RENX can achieve their growth ambitions then the share price will take care of itself. @Nimbo I note Livongo smashed their Q2 target by around 20% ($86m revenue), the full year forecast was $300m (likely to be upgraded by a decent amount!), and they’re now valued at $9b so 30x revenue. The critical next step for RENX is recording first revenues via Mount Sinai, hopefully in the very near future...
74tom
07/7/2020
13:59
We are on an escalator it seems, there will be sellers all the way up - some people are already up 5x from ipo price!
nimbo1
07/7/2020
07:56
I note Legal & Generals reduced stake. Clearly from Renalytix most recent announcement, pharma are interested - "Data sharing agreement with top ten global pharmaceutical company enables investigation of repeat testing with KidneyIntelX and prediction of therapeutic response" This is an area I have looked into previously (albeit I am no expert). Who might the top 10 pharma be? Depends of whether that's based on revenues or value, but the list of candidates is broadly similar - hTTps://www.pharmaceutical-tech.com/articles/top-10-pharmaceutical-companies-in-the-world The next aspect I considered is SGLT2 Inhibitors which are used to treats Type 2 diabetes, but have a number of side effects including kidney injury - hTTps://www.drugwatch.com/sglt2-inhibitors/ For 'example' - Nephrologists Are Hesitant to Fully Embrace Janssen's INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease June 18, 2020 /PRNewswire/ -- Millions of patients across the United States suffer from Type 2 diabetes, and one-quarter or more of those patients also have kidney disease, making diabetic kidney disease (DKD) one of the largest causes for morbidity and mortality in the country. Janssen's INVOKANA was approved in late 2019 as the first sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and DKD (nephropathy) with a certain amount of protein in the urine. Yet, nephrologists are reportedly still not entirely comfortable with this class. hTTps://www.prnewswire.com/news-releases/nephrologists-are-hesitant-to-fully-embrace-janssens-invokana-despite-being-the-first-and-only-sglt2-inhibitor-with-an-fda-indication-to-treat-diabetic-kidney-disease-301079788.html
wan
03/7/2020
15:10
hxxp://www.mediscience-event.co.uk/awards/shortlist/ shortlisted for best technology award at European mediscience awards...
nimbo1
02/7/2020
17:44
According to Sharepad only the second ever 1m volume day here, the last time was September 2019 when the price was £2.42. In terms of value traded it's 2 x the nearest day. No doubt Sahara's excellent thread stirred some PI interest this morning, but we undoubtedly saw some II activity this afternoon, with 2 x 100k buys offset against multiple 25k sells. Fingers crossed everything continues smoothly, but it appears that RENX is heading for the major leagues.
74tom
Chat Pages: 24  23  22  21  20  19  18  17  16  15  14  13  Older
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200807 01:41:08